California Supreme Court backs Gilead, exposing how IP law limits drug innovation and deepens health inequities
Original framing: “STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case” — STAT News
Scientific evidence shows that the majority of new molecular entities rely on publicly funded basic research, with private firms mainly handling later-stage development and marketing. Studies also indicate that stronger patent protection does not correlate with higher rates of breakthrough therapies, but does increase drug prices. The court's decision overlooks this evidence, conflating patent exclusivity with genuine scientific advancement.
The California Supreme Court's ruling underscores how entrenched IP structures, historically shaped to favor corporate profit, continue to marginalize patients and ignore the contributions of public and Indigenous knowledge.
Cross‑cultural examples demonstrate viable alternatives that balance innovation with equitable access, while scientific data reveal that strong patents do not guarantee therapeutic breakthroughs. By integrating future modelling, artistic‑spiritual insights, and trickster critiques, we see that the current legal framing paradoxically hinders the very creativity it claims to protect. Systemic reform—through legal duty to disseminate, equitable funding mechanisms, global patent pools, and community oversight—offers a pathway to align drug innovation with public health imperatives.